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Abstract 
 
The work aims to prove the complexation of two models drugs (ibuprofen, IB and 
indomethacin, IN) by beta-cyclodextrin (βCD), the effect of the water in such process, 
and the comparison of their complexation yields. Two methods were considered: 
kneading of a binary mixture of the drug:βCD and inclusion of either IB or IN in 
aqueous solutions of βCD. In the latter method the water was removed by air stream, 
spray-drying and freeze-drying. To prove the formation of complexes in final products 
optical microscopy, UV spectroscopy, IR spectroscopy, DSC, X-Ray and NMR were 
considered. Each powder was added to an acidic solution (pH = 2) to quantify the 
concentration of the drug inside βCD cavity. Others media (pH = 5 and 7) were used to 
prove the existence of drug not complexed in each powder as the drugs solubility 
increases with the pH. It was observed that complexation occurred in all powders, and 
that the fraction of drug inside the βCD did not depend neither on the method of 
complexation nor on the processes of drying considered.  
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spectroscopy, DSC 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
1. Introduction 
The therapeutic activity of drugs is related to their solubility in water. To improve 
the solubility of a drug, various techniques can be considered namely micronisation, 
nanosizing, microemulsification, formulation in an amorphous solid form (e.g. solid 
dispersions by melt extrusion) or the modification of the physicochemical properties of 
the drug (e.g. salt formation and water soluble complexes formation)  
[1, 2].  
Cyclodextrins (CDs) are cyclic oligosaccharides with a lipophilic cavity and a 
hydrophilic outer surface which contain 6 (α), 7 (β) and 8 (γ) glucose units with 
different solubilities which can be further improved by chemical modifications on its 
molecular structure.  These compounds have the ability to form inclusion complexes by 
taking up a whole molecule or rather some non polar parts in its hydrophobic cavity  
[3-9]. The driving forces between hosts and drugs which have been proposed to justify 
the complex formation are hydrogen bonds, van der Waals forces, hydrophobic 
interactions and the release of “high energy water” molecules from the cavity [10]. 
During the drug-βCD complex formation no covalent bonds are formed or broken which 
stresses the physical rather than chemical nature of the process [1]. The complexes 
improve the characteristics of the drugs such as solubility, chemical stability (due to 
hydrolysis, oxidation, photodecomposition and dehydration of the drug), bioavailability 
and reduction of drugs side effects [1, 10]. A number of different methods have been 
applied to enhance the complex efficiency of the CDs: ionization of the drug, salt 
formation, formation of the metal complexes and addition of organic cosolvents to the 
aqueous complexation media and the use of supercritical fluids all promote the 
enhancement of the intrinsic solubility of the drug-favouring complexation [3, 9, 11].  
The model drugs used in this study were NSAIDs: ibuprofen (pKa value of 4.4) 
and indomethacin (pKa value of 4.5) which is known to exist in more than one no-
solvated crystalline modification (three polymorphs α, β, γ). Both drugs are pH-
dependent and practically insoluble in water [12-15]. These drugs were selected due to 
their low solubility and high permeability (Class II, Biopharmaceutical Classification 
System, BSC [16]) and thus the increase on their solubility will improve their 
bioavailability.  
The aim of this work is to provide evidence that the yield of complex formation 
between βCD and two NSAIDs do not depend on the amount of water used in the 
preparation of the solid complexes by kneading or solution/suspension methods used. In 
the solution/suspension method of complexation, water was removed by spray-drying 
(SD), freeze-drying (FD), and air stream drying (AS), as described by Miller et al [17].  
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2. Materials and methods 
 
2.1. Materials 
 
(±)-Ibuprofen 20/35, (racemic α-methyl-4-[2-methylpropyl] benzene acetic acid, IB) 
and Indomethacin (1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid, IN) 
were purchased from Capsifar (Portugal). β-cyclodextrin (βCD) was purchased from 
Wacker (Germany). Demineralised water (pH = 4.5-5.0) was used in the study. 
 
2.2. Methods 
 
2.2.1. - Phase Solubility Studies 
 
Phase solubility studies of the individual components were carried out according 
to the method of Higuchi and Connors [18]. Aqueous solutions of βCD at different 
concentrations (0, 3, 6, 9 and 12*10-3 M) at pH ≈ 6, were added to each one of the two 
drugs, in amounts above their solubility, in capped tubes. The tubes were placed in a 
water bath at a constant temperature (± 25ºC) and were shacken in horizontal 
movements (100/min) for a period of time to allow equilibrium: 8 hours for the 
indomethacin and 10 hours for the ibuprofen. After these periods the concentrations did 
not change. Samples were collected and centrifuged (Sigma 112, B. Braun Biotech 
International, Germany) at 13,000 r.p.m. (10 min) in eppendorf tubes prior to the 
quantification of the drug by ultraviolet spectroscopy analysis (U-200, Hitachi, Japan). 
Phase solubility curves were represented as the total dissolved drug concentration 
against the concentration of βCD. The binding constant (K1:1) for each complex was 
calculated from the slope of the straight-line portion of the curve, according to the 
following equation [18]: 
 
)1(01:1 slopeS
slope
K
−
=
             (1) 
 
where, S0 is the solubility of the drug in the absence of βCD. 
2.2.2. - Preparation of the complexes 
 
The particle sizes of the materials used in this study were less than 250 µm. The 
βCD was dissolved in an amount of water approximately equivalent to its solubility 
(1.63 M at 25ºC) and each drug was added in 1:1 stoichiometric ratio in corresponding 
amounts to produce 100 g of the final mixture. The systems of βCD with each drug 
were shacken (250 r.p.m.) at 25 ± 1ºC for a pre-determined time (8 h for IN and 10 h for 
IB correspond dynamic equilibrium from the solubility studies).  
Before removal of water, the pH value was determined in the supernatant and 
samples of each suspension were collected for the determination of the drug 
concentration. Water was removed by spray-drying (SD) (Büchi MiniSpray Dryer B-
191, Switzerland: inlet temperature 125ºC, outlet temperature 98ºC, aspirator set at 
100% and flow rate set at 2.3 ml/min) and by freeze-drying (FD) (Christ Alpha 1-4, B. 
Braun Biotech International, Germany: samples were previously frozen at -20ºC and 
then dried at 0.0045-0.0070 mbar). In a different set of experiments, drying was 
performed by exposing the suspensions to a stream of air (AS) at room temperature. A 
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physical mixture (PM, regarded as control) and the mixture for kneading (K) were 
prepared in flasks by shaking them for 10 min (Fisher-Kendall Scientific Co, 12-811, 
USA). Kneading was carried out by adding water (20 ml/5 min) (30, 70% - IB and 50, 
70% - IN w/w) in a mortar, and the mass was triturated with a pestle. The water in the 
mixture was removed by evaporation under stirring. The dried binary mixtures obtained 
by the four methods were sieved (250 µm) and, if necessary, the binary mixtures were 
ground in a mortar with pestle for the production of particles with less than 250 µm in 
diameter.  
Samples of the powders (AS, K30, FD for IB and AS, K70, FD for IN) were 
washed with diethyl ether (Merck, Germany) to remove the drug not complexed in order 
to confirm the presence of the inclusion complex in the powders [19]. Drugs were 
identified by ultraviolet spectroscopy (samples with an asterisk). 
The preparation of complexes by melting of the components in an oven (Heraeus, 
Germany) has also been tried. The powders were weighed in  
1:1 stoichiometric ratio and then placed in an oven (IB-βCD: 120ºC and IN-βCD: 
200ºC). These temperatures were chosen to assure the melting of the drugs [20]. 
 
2.2.3. – Characterisation of the complexes 
 
2.2.3.1. - Optical microscopy (OM) 
Raw materials and all powders were observed through a microscope (Olympus 
CX40 RF200 coupled with an Olympus C-5050 photographic system 5 megapixels, at 
40 and 200 times magnification Olympus, Japan) and the images registered. 
 
2.2.3.2. - Differential scanning calorimetry (DSC) 
All powders were analysed by DSC (TC 11, TA Processor, Mettler, Germany) to 
identify their thermal behaviour: 5-6 mg of each powder in aluminium pans was heated 
at 5ºC/min from 30 up to 300ºC. The powders produced by AS drying, FD and K were 
also evaluated for thermal behaviour after being washed with diethyl ether. 
 
2.2.3.3. - Spectroscopic evaluation 
Ultraviolet spectroscopy (UV): identification of drug (IB and IN) in complexes, 
previously washed with diethyl ether, was performed by scanning from 380 to 190 nm 
(Hitachi U-2000, Japan) and compared to the absorbances of IB (at 221 and 263 nm) 
and IN (at 196, 265 and 319 nm) in the complexes with those produced by the free drug. 
 
Fourier Transform Infrared spectroscopy (FT-IR): FT-IR spectra were obtained 
for each raw material and for the mixtures of powders (Nicolet spectrophotometer, 
model Impact 400, USA) using a KBr disk method and scanned in the range of 4000 to 
450 cm-1. Furthermore some mixtures were washed with diethyl ether (AS*, FD* and 
K*) and also submitted to characterisation by FT-IR.  
 
Nuclear magnetic resonance (NMR): all the 1H NMR spectra were recorded at 
300 MHz (Bruker AVANCE II+ spectrometer, Germany). The βCD anomeric proton 
H(1) was used as internal reference (0 ppm) for the magnetic shift units, as described in 
the literature [21], since its location insures the smallest shift and the residual protons in 
deuterated water are too large and may undergo exchange with small amounts of non-
deuterated water [21]. The measurements were performed at 40ºC.  
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X-ray diffractometry (XRD): the XRD measurements on the samples from the 
mixtures of the powders were performed using a variable-geometry device equipped 
with a Max-Flux Optic graded multilayer monochromator (CuKα radiation) and a gas 
curved counter “INEL CPS 590” that was associated with a data acquisition computer-
controlled system. The measurements were performed at room temperature (22ºC). 
 
2.2.4. - Assay of the drug in the mixtures  
 
The total drug content (free and in the complex) present in each powder was 
determined by UV spectrophotometry: 10 mg of each powder was dissolved in 100 ml 
(IB) or in 250 ml (IN) of a hydroalcoholic solution 1:1 (v/v) in which both are 
completely dissolved. All solutions produced were submitted to ultrasonication 
(Branson 5200, USA) for 25 min to assure a complete dissolution of the drug, i.e., 
100% of the weighted drug. 
The inclusion yield (%) for the drug processed according to the different 
techniques was assessed at different pH values (pH = 2, 5 and 7, phosphate buffer) [22]. 
Samples of 20 mg of the each mixture powder were suspended in 20 ml of phosphate 
buffer solution, ultrasonicated for 3 min, centrifuged (Megafuge 1.0R, Heraeus, 
Germany) at 3500 rpm for 15 min and the dissolved drug in the supernatants was 
quantified by UV spectrophotometry.  
 
 
3. Results and discussion 
3.1. - Phase solubility 
The dynamic equilibrium was reached up to 8 hours for IN and 10 hours for IB, as 
determined in the phase solubility studies. These studies showed that, the maximum 
amount of IB dissolved reached a constant concentration at 6*10-3 M βCD, 
characteristic of a Bs type diagram leading to an insoluble precipitate made of both free 
and complexed drug (Fig. 1A). On the other hand, the solubility of IN increased linearly 
with the concentration of βCD, characteristic of an AL type solubility diagram [18], i.e., 
formation a 1:1 complex. In this case, the sediment is only made of drug (Fig. 1B). For 
IN the apparent stability constant, reflecting the extension of inclusion, was determined 
taking into consideration all points in the curve (K1:1 = 366 M-1), whereas for the IB 
only the first three points of the curve were considered, i.e., the linear portion (K1:1 = 
2016 M-1). K1:1 values show that the process of the inclusion is easier for IB than IN, 
that may be partly explained by the fact that the molecular structure of IB is simpler 
(lower molecular weight and less aromatics groups) than the structure of the IN. 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
 
 
 
 
 
 
Fig. 1.   Phase solubility analysis for A) ibuprofen and B) indomethacin. 
 
3.2. - Physical aspect 
Throughout and after kneading process, the preparation of powders by the 
addition of water originates products with different consistencies (Fig. 2): IB-βCD K30 
was easier to mix than IB-βCD K70 (Fig. 2, a1 versus a2); the particles in the first mass 
agglomerated whereas in the second produced a very hard mass. On the other hand, both 
IN-βCD K formulations were easily mixed with water ending up in a liquid (Fig. 2,  
b1 versus b2).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.   Aspect of the powders produced by kneading at the end of the preparation. 
 
 
Table 1 presents the results of the fractions of drugs in the supernatant dissolved 
as complexes of the suspensions, before drying. The value for IB shows that the 
percentage of the drug-βCD complex dissolved is lower when compared with the values 
obtained after reconstitution of the dried powder (26.77% versus 78.95%). This might 
be explained by the partial precipitation of the drug-βCD complex (profile Bs in the 
solubility diagram [18]) together with the free drug. By contrast, the values for IN have 
shown that the percentage of the drug-βCD complex dissolved is comparable to the  
values obtained after reconstitution of the dried powder (0.83% versus 0.95%, FD). The 
observation might explained by the fact that the entire drug in the complex is dissolved 
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in the medium, whereas the sediment is made of the free drug only. The stability of the 
IN-βCD complexes decreased as the drug became ionized as the pH increased due to 
decrease on the interaction with the hydrophobic cavity of the CD [23]. 
 
 
 
The differences observed in the particles regarding their shape and size  
(<250 µm) for all powders are related to the step of grinding (Fig. 3). The particles of 
βCD present a rectangular shape, while IB particles have shown a well-defined rod 
shape and IN particles present an irregular shape. The powders which contain free IB 
and βCD and IB-βCD complex (except IB-βCD PM, Fig. 3) present particles with 
different shapes, which can be related to the new entity formed (complex) and to the 
drying methods. The powder produced by PM is made of particles with rod (IB) or 
rectangular (βCD) shapes.  
The shape of the particles did not change throughout the process because they 
were submitted to the process of the mixture, only. On the other hand, the particles 
produced by AS showed different shapes when compared with the ones produced by 
PM due to the existence of a new entity (complex), which are irregular in shape 
produced by the evaporation of the solvent and crystallisation. The few particles found 
with IB shape correspond to the free IB. The other powders [K, SD (not shown) and 
FD] have shown particles with irregular shapes corresponding to new entities 
(complexes).  
The small size of these particles can be related to the method of drying and to 
grinding: powders containing free IN and βCD and IN-βCD complex (except IN-βCD 
PM, Fig. 3), show the same difference in the shape of the particles. It seems that the 
method of drying is critical on designing the size and shape of the particles. Due to the 
fact that the complexation yield is very low (0.82-0.95%, Table 1), the number of 
particles produced is not sufficient to provide evidence related to changes of particles of 
IN-βCD in comparison with the raw materials. As anticipated the powders produced by 
PM have shown particles with the same shapes for IN (irregular) and for βCD 
(rectangular). Particles from powders produced by K or SD (not shown) present smaller 
sizes but identical shapes to the PM powders. On contrary, powders produced by FD 
have shown particles with different shapes: a possible explanation might reside on the 
fact that the complex was not present in a high enough amount for its effect to be 
significant. Again, the size of the particles is very low and can be related to the method 
of drying and grinding. 
 
Table 1 
Amount of drug dissolved as complex form in the supernatant 
 
 Concentration (%)a 
Ibuprofen IB-βCD SD 26.77 ± 0.86 
   
Indomethacin IN-βCD SD 0.83 ± 0.04 IN-βCD FD 0.82 ± 0.02 
a) Mean±sd (n=3)   
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Fig. 3.   Photographs of the powders considered in the study: raw materials and products 
from the physical mixture containing the drug-βCD complex, as observed by optical 
microscopy. 
 
 
 
IB-βCD AS 250 µm IB-βCD AS 50 µm IN-βCD AS 250 µm IN-βCD AS 50 µm 
250µm IB 50 µm IB IN 250µm IN 50µm 
βCD 250µm βCD 
 
50µm 
IN-βCD PM 250 µm IN-βCD PM 50 µm IB-βCD PM 50 µm 250µm IB-βCD PM 
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3.3. – Differential scanning calorimetry 
 
3.3.1 – Ibuprofen 
 
The thermograms from the mixtures of powders and raw materials show 
characteristic thermal behaviours. The comparison between the endothermal transitions 
of IB, βCD, IB-βCD PM and IB-βCD complexes shows that the powders containing 
complexes present a temperature shifted-βCD endotherm (Fig. 4A). The characteristic 
endothermic transition of βCD (Fig. 4Ab) and IB-βCD PM (Fig. 4Ac) ranges between 
100-145ºC. The analysis of other endothermic transitions (Fig. 4Ad-h), regarding the 
βCD, shows shifts on the temperature endotherm to a lower value range (80-120ºC). 
This change of the endotherm in the latter powders could provide evidence of the 
complex formation after comparison to βCD and IB-βCD PM endothermic transitions. 
The shape of the βCD endotherm is changed in all powders containing complexes, 
although the endothermic transitions for powders produced by kneading (K) were less 
obvious (Fig. 4Ae,f). The modification on the shape of the endotherm´s line was 
attributed to the dehydration of the βCD-ring cavity [14]. This dehydration is more 
obvious for FD, SD and AS samples than for the K processes. The endothermic due to 
the melting of IB are present at 76.3ºC (Fig. 4Aa). The other values due to the melting 
endotherm of the IB on the different powders are present at 74.8ºC for PM (Fig. 4Ac), 
74.6ºC for AS (Fig. 4Ad), 74.5ºC for K30 (Fig. 4Ae), 75.1ºC for K70 (Fig. 4Af) and 
74.9ºC for FD (Fig. 4Ah). The shape of the IB endotherm in the thermograms for all 
powders (except IB-βCD SD) shows that the free IB is present, i.e., the yield of the 
inclusion process is not 100%. The absence of an IB endotherm in the powder submitted 
to SD (Fig. 4Ag) can be due to the temperature conditions used in this method (inlet 
temperature 125ºC). This temperature, higher than the melting temperature of the drug, 
can be responsible for the disappearance of the free drug present in the powder. The 
powders containing binary systems present similar values for the melting point. 
 
3.3.2 – Indomethacin 
 
For the IN, the comparison on between the thermograms shows a slight 
temperature shifted-βCD endotherm on the temperature (Fig. 4B). The characteristic 
endothermic transition of βCD (Fig. 4Bb) ranges between 99-145ºC. The analysis of the 
other endothermic transitions (Fig. 4Bc-h) concerning βCD, shows shifts of the 
temperature of the endotherm to a lower value range (93-140ºC). This decrease is not 
very obvious because the yield of the inclusion process for this drug is low and, thus, 
the percentage of the binary systems for different powders presents very low values. 
The large amount of free βCD in all different powders led to a similar dehydration 
behaviour in all of them. The shape of the βCD endotherm in all the powders shows 
only a small change reflecting a low yield of inclusion. The appearance of an IN 
endotherm in all thermograms shows that free IN is present in all binary systems. This 
proves that the yield of inclusion is bellow 100%. The endothermic relative to the 
melting of IN are present at 160.9ºC (Fig. 4Ba). The other values corresponding to the 
melting endothermic transition of IN on the different powders is present at 161.5ºC for 
PM (Fig. 4Bc), 162.2ºC for AS (Fig. 4Bd), 161.1ºC for K50 (Fig. 4Be), 161.0ºC for K70  
(Fig. 4Bf), 160.7ºC for SD (Fig. 4Bg) and 161.7ºC for FD (Fig. 4Bh). These values 
correspond to Form I polymorph for this drug [15].  
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3.3.3. – Samples washed with an organic solvent 
 
Fig. 4C and D shows the characteristic thermograms of some powders mixtures 
after being washed with diethyl ether to remove the free drug. The thermograms of the 
complexes (Fig. 4Cc-e and 4Dc-e) only presented endothermic transitions corresponding 
to the βCD. Furthermore these powders were submitted to ultraviolet scanning showing 
maxima of absorbance characteristic for each drug identical to the ones observed for the 
pure drugs. These data provide evidence of inclusion complex formation of the drugs 
into βCD. 
 
Fig. 4.   Thermograms of A) and B) drug, βCD, drug-βCD physical mixture and drug-
βCD complexes; C) and D) drug, βCD and drug-βCD complexes washed with diethyl 
ether. 
 
0 100 200 300
Temperature (ºC)
d 
h
g
f
e
c
a
b
ibuprofen 
a) IB; b) βCD; c) IB-βCD PM; d) IB-βCD AS; e) IB-βCD K30;  
f) IB-βCD K70; g) IB-βCD SD; h) IB-βCD FD 
 
A) 
0 100 200 300
Temperature (ºC)
a
g
e
d
c
b
h
indomethacin 
a) IN; b) βCD; c) IN-βCD PM; d) IN-βCD AS; e) IN-βCD K50;  
f) IN-βCD K70; g) IN-βCD SD; h) IN-βCD FD 
 
f
B) 
0 100 200 300
Temperature (ºC)
a
b
c
d
e
a) IB; b) βCD; c) IB-βCD AS*; d) IB-βCD K30*; e) IB-βCD FD* 
 
 ibuprofen 
C) 
0 100 200 300
Temperature (ºC)
a
b
c
d
e  
indomethacin 
a) IN; b) βCD; c) IN-βCD AS*; d) IN-βCD K70*; e) IN-βCD FD* 
 
D) 
 12 
3.4. – FT-Infrared spectroscopy 
Samples of raw materials and powders were analysed by FT-Infrared 
spectroscopy (FT-IR). The spectral region from 4000 to 3000 cm-1 is difficult to analyse 
for βCD and its complexes due to primary and secondary 'OH' groups of βCD and water 
molecules of crystallization. The symmetrical bending band of water in βCD hydrate 
appears at 1644.7 cm-1 (1650-1630 cm-1 [14, 24, 25]) (Fig. 5a). The intensity of this 
band was used as an internal reference for the water content in the βCD samples [22]. In 
all spectra, this band presented a small shift due to changes in the hydrated bonds within 
βCD [14]. 
 
3.4.1. – Ibuprofen 
 
The spectrum of the IB shows the presence of a stretching band at 1721.3 cm-1 
correspondent to the carbonyl group ('C=O', from a carboxylic acid group). The 'C=O' 
stretching bands of acidic groups are considerably more intense than ketonic 'C=O' 
stretching bands. Two bands arising from 'C=O' stretching and 'OH' bending appear in 
the spectra of carboxylic acids 1422.7 and 1320.0 or 1225.0 cm-1 (1440-1395 and 1320-
1210 cm-1 [25]), respectively (Fig. 5a1) [25]. The analysis of the spectra from powders 
K30*, and FD* (*denotes washed samples) (Fig. 5c1 and c2) shows the acid carbonyl 
stretching band shifted to a higher frequency (1729.6 cm-1). This shift in wavelength 
might be due to the breakdown of intermolecular hydrogen bonding of the crystals, 
strengthened by ionic resonance, associated with the IB dimmers and the establishment 
of weaker forces. It follows that, the formation of a monomeric dispersion of the drug, 
as a consequence of the interaction with βCD could result in the inclusion of the drug 
monomer into the hydrophobic cavity of the CD. In the spectra of IB-βCD PM (Fig 5b1) 
the carbonyl stretching band appeared at the same wavenumber (1721.3  
cm-1) of the pure drug IB (Fig.5a2) [14, 25-31]. Other spectra (not shown) presented 
shifts in this peak which corresponds to the carbonyl group (1737.4 cm-1 for IB-βCD 
AS, 1742.9 cm-1 for IB-βCD SD, 1743.2 cm-1 for IB-βCD FD, 1736.0 cm-1 for IB-βCD 
AS* higher frequency and 1708.5 cm-1 for IB-βCD K30 and 1709.1 cm-1 for IB-βCD 
K70 lower frequency). The shift of a band on the corresponding carbonyl group proved 
the presence of the solid complex formation suggested this group was not fully included 
within the CD cavity. 
Several authors [26, 28, 32] have shown that by molecular modelling it is possible 
to predict the conformation of the complex of the IB into the βCD cavity with a slight 
inclination. The portions of the drug molecule inside the βCD cavity are the isopropyl 
group and a part of the aromatic ring. 
 
3.4.2. – Indomethacin 
 
The spectrum of the IN has shown the presence of two bands around 1721.3 and 
1689.4 cm-1 corresponding to the carbonyl group (both ketone and carboxylic acid 
contributions). The fact this group shows a strong stretching absorption band in the 
region of 1870-1540 cm-1 is due to a constant position, high intensity and freedom from 
interfering bands, which make it useful to recognize in the IR spectra [25, 33]. The 
range between 900-600 cm-1 presents more intense and informative bands in the spectra 
of aromatic compounds [15, 25] (Fig. 5a3). An examination of all spectra obtained from 
powders with binary systems produced with IN, not submitted to washing process with 
the organic solvent (not shown), revealed two small but distinct bands at 1721.3 and 
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near 1689 cm-1 (carbonyl groups), which prove the existence of the free drug in the 
powder (1685.7 cm-1 for IN-βCD AS, 1685.7 cm-1 for IN-βCD K50, 1689.4 cm-1 for IN-
βCD K70, 1685.7 cm-1 for IN-βCD SD and 1685.7 cm-1 for IN-βCD FD) [25, 31]. These 
bands occur in IN-βCD PM (Fig. 5b2). Moreover, the spectrum showed small peaks 
around 1312 cm-1 which were attributed to 'C-H' bending, 'C-O' stretching and 'O-H' 
deformation absorbances within IN (i.e., groups not fully included within the βCD) [14, 
26-29]. The other bands in the IR spectra from the complexes were similar to pure βCD 
and dissimilar to the corresponding pure drug (Fig. 5c3 and c4). The samples, after being 
washed with diethyl ether, have presented spectra without bands due to carbonyl groups 
but showing the peaks at 1634.1 cm-1 for IN-βCD AS* (not shown), 1640.9 cm-1 (IN-
βCD K30)* and 1634.1cm-1 (IN-βCD FD*) corresponding to a change in the hydrated 
bonds within βCD. The disappearance of the bands due to carbonyl groups of IN on the 
complex spectra (washed samples) about 1689.0 cm-1 suggests the inclusion of the two 
carbonyl groups into the CD cavity (Fig. 5c3 and c4) [14]. 
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Fig. 5.  Infrared spectrum of the drug-βCD: A) ibuprofen and B) indomethacin a) raw 
materials (a1, a2 and a3); (b) physical mixture (b1 and b2); (c) complexes after washing 
with diethyl ether (c1, c2, c3 and c4). 
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3.5. – Nuclear magnetic resonance 
 
NMR proton spectroscopy has been a frequently used spectroscopic analytical 
tool to study the inclusion of guest molecules into a host [5, 10, 21, 34]. Here we have 
addressed the possible inclusion/complexation of the two drugs considered (IB and IN) 
in a host macrocycle (βCD) with simple 1D proton spectroscopy, combined with other 
complementary characterisation techniques. It was possible to record four proton 
spectra of aqueous saturated solutions (in D2O) of IB-βCD and IN-βCD powders, 
submitted and not submitted to a previous washing procedure. These spectra were 
compared to the spectrum of a βCD solution in order to identify line shifts that could 
provide evidence for a complexation phenomena, and to study the possible effect of the 
washing procedure on both powders [35]. It is well known that βCD has the topology of 
a hollow cone shape, with the H(3) and H(5) being inner protons. Many other inclusion 
studies point to a spatial arrangement where the hydrophobic guest molecules penetrate 
in the toroidal cavity, forming inclusion complexes that mainly affect the inner protons 
of the macrocycle. Therefore, our study should focus in first place on the behaviour of 
the βCD protons in the H(3) and H(5) chemical shift range. Comparing the βCD 
solution spectrum and the spectra of the non-washed powders of ΙΒ-βCD and ΙΝ-βCD 
(Fig. 6A), a significantly induced chemical shift (up-field) for the inner protons H(5) 
and H(3) in both samples is easily recognized, this effect being stronger in the IB-βCD 
powder mainly for H(5). The formation of a complex by inclusion is clearly put in 
evidence by these spectral features which may be the result of either a higher inner 
proton H(5) shielding in the βCD cavity or a larger stability at the equilibrium between 
complexes and free species (or both) [26, 28].  
 
 
 
Fig. 6. Chemical shifts of protons in solution (reference H(1) at 0 ppm) produced by 
NMR:  
A) pure compound (a) and of the non-washed mixtures (b and c);  
B) chemical shift diferences of each βCD proton H(i), (i=1,…, 6) between the shifts of 
the pure βCD (a) and the shifts in the IB-βCD (b) and IN-βCD (c)  mixtures (non-
washed). 
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Table 2 shows the chemical shifts of the central point of the βCD proton 
multiplets, in simple solution and in the presence of complex forming agents, in non-
washed powders, with reference to the H(1) proton, as well as the shift differences 
between equivalent spectral points of the βCD solution and each one of the powder 
solutions: ΙΒ-βCD and ΙΝ-βCD. These results are shown in Fig. 6B, in which the larger 
shift for the H(3) and H(5) protons and the stronger shift effect for the ΙΒ-βCD are 
immediately quantified which may be the result of either a higher inner proton H(5) 
shielding in the βCD cavity or a larger stability in the equilibrium between complexes 
and free species (or both) [26, 28].  
 Applying the same NMR proton analysis to the washed ΙΒ-βCD and ΙΝ-βCD 
powders, the same shift effects are observed in the latter, but there are no relevant 
modifications with respect to the ΙΝ-βCD system spectra. We have to draw the 
conclusion that the IN, which is present at a very low concentration in the solution due 
its low solubility, was substantially removed from the host βCD molecule by the 
washing operation, in opposition to the ΙΒ-βCD powder.  
 
 
 
3.6. – X-ray diffractrometry 
Fig. 7A presents the X-ray scattering pattern obtained from samples containing 
different powders. By comparing the patterns (d) and (e) from the washed powders with 
the patterns from βCD (a) and IB (b) one can observe that the scattering peaks found in 
patterns (d) and (e) are very similar to each other when registered but not to the 
scattering peaks registered in pattern (a) or (b). This is an indication that a new entity is 
being observed in patterns (d) and (e) relative to patterns (a) and (b) and thus 
corresponds to the inclusion complex. The absence of peaks from either βCD or IB on 
patterns (d) and (e) means that the amounts of these substances (if exist) are beyond 
detection and this arises because free IB was removed through washing and βCD 
remains in a too small fraction for detection due to a high inclusion yield. By observing 
the scattering pattern from the non washed powder complex (IB-βCD) one finds all the 
peaks found in patterns (d) and (e) correspond to the inclusion complex and extra peaks 
Table 2 
Chemical shifts of the βCD protons in the NMR spectra of the compound and of its mixtures 
with IB and IN 
δ (ppm) H(1) H(2) H(3) H(4) H(5) H(6) d dd t t m m 
βCD(δi A) 0.000 -1.431 -1.122 -1.488 -1.246 -1.182 
IB-βCD(δi B) 0.000 -1.429 -1.162 -1.466 -1.342 -1.219 
IN-βCD(δi C) 0.000 -1.438 -1.130 -1.468 -1.293 -1.192 
∆
i
 BA=( δi B- δi A) 0.000 0.002 -0.040 0.023 -0.096 -0.037 
∆
i
 CA=( δi C- δi A) 0.000 -0.008 -0.007 0.020 -0.047 -0.010 
Chemical shifts of the H(i) protons (i=1,… 6) of βCD (δΑi) and IB-βCD (δΒi) and in IN-βCD (δCi) non-washed 
mixtures in solution [ppm values with H(1) as reference]. ∆iBA (in the IB-βCD mixture) and ∆iCA (in the IN-βCD 
mixture). These values are represented in the Fig. 6B. 
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that where registered along with peaks from IB (pattern b) corresponding to the free IB. 
The absence of peaks from non complexed βCD is caused by a low percentage of this 
component in the powder as discussed above [31, 36, 37]. Fig. 7B presents X-ray 
scattering patterns obtained from samples containing different powders. By comparing 
the pattern (c) from the non washed powder with the patterns from βCD (a) and IN (b) 
one can observe that the scattering peaks found in pattern (c) are all in registered the 
scattering peaks in pattern (a) or pattern (b). No new scattering peaks are present in 
pattern (c) relative to both patterns (a) and (b) indicating that the amount of complex is 
beyond detection in this powder. Pattern (d) from the washed powder shows scattering 
peaks in registered with the pattern (a) without any contribution from pattern (b) 
indicating that once more the amount IN-βCD complex is beyond detection, and the free 
IN was efficiently removed with the washing process [20, 31, 38]. The lack of evidence 
for the presence of complex in both samples (c) and (d) may have its origin on the very 
low yield of the inclusion process for IN on βCD with an estimated yield of 0.82 to 
0.95%. 
 
Fig. 7. X-ray scattering patterns obtained from samples containing powders: A) 
ibuprofen and B) indomethacin. 
 
3.7. – Assay 
 
The contents (%) of each drug in all the binary systems powders are showed in 
the Table 3 (IB and IN). All values, except IB-βCD SD value are into the interval of  
100 ± 5%. The low value of the IB-βCD SD has been addressed previously, when the 
results from the calorimetry studies were discussed. Table 4 (IB and IN) presents the 
amounts (%) of free drug and drug as a complex form from each powder dissolved at 
different values of pH.  
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At pH 2 the amount of IB dissolved as a complex form was practically the same 
for all powders, except IN-βCD PM. At these levels, the amount of drug dissolved from 
IB-βCD PM is smaller because this powder does not contain IB in the complex (Table 
4). This content is higher than free IB due to the fact that during the preparation of the 
solution some complex was formed. At pH 5 an increase of the amount of drug 
dissolved occurred, because a part of the free drug was dissolved at this pH. At pH 7, all 
powders present the largest values because at this pH the drug dissolved results from the 
free and the complex drug. At this pH, the IB presented a solubility of 1.0 mg/ml at 
20ºC [12]. For the different pH values, the amount of IB-CD SD did not increase maybe 
due to the previously explained in section 3.3.1. 
At pH 2, the amount of IN dissolved as a complex form was practically the same 
for all powders, except IN-βCD PM. The amount of drug dissolved from IN-βCD PM is 
lower because this powder did not contain IN as a complex. This content is higher than 
free IN due to the fact that during the preparation of the solution some complex might 
have been formed. At pH 5, an increase of the amount of drug dissolved occurred, 
because a part of the free drug was dissolved at this pH [15]. At  
pH 7, all powders presented the largest values of the drug that dissolved because for this 
value of pH, part of the drug dissolves as a non-complexed salt and drug as a complex 
form. At this pH the IN, Form I, presents a solubility of 54 mg/100 ml at 25º C [15]. 
 
 
 
 
 
Table 3 
Amount of total drug in each powder 
 
 Concentration (%)a 
Ibuprofen 
IB-βCD PM 96.35 ± 0.18 
IB-βCD AS 96.00 ± 0.26 
IB-βCD K30 97.70 ± 0.09 
IB-βCD K70 99.65 ± 0,33 
IB-βCD SD 76.97 ± 0.00 
IB-βCD FD 102.42 ± 0.09 
 
Indomenthacin 
IN-βCD PM 97.23 ± 0.11 
IN-βCD AS 99.15 ± 0.12 
IN-βCD K50 96.02 ± 0.00 
IN-βCD K70 97.03 ± 0.20 
IN-βCD SD 96.05 ± 0.12 
IN-βCD FD 99.92 ± 0.49 
a) mean±sd (n=3)   
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4. Conclusions 
The results obtained from the different preparations have shown the presence of 
a complex in each powder. Water is necessary to promote the inclusion but its amount is 
not so important if the intrinsic solubility of the drug is not modified. The results of the 
formation of the inclusion complex obtained from the different methods related to 
interactions in an aqueous solution and in the solid state suggest a mechanism of 
complexation by inclusion of the drug in the cavity of the βCD, process that is similar 
for all the techniques and drugs considered. The kneading process showed the same 
yield as the other methods tested with several advantages, namely more economic and 
less time consumption to obtain the complex. The different analytical methods 
considered (DSC, IR, X-Ray and NMR) in combination provided evidence of the 
complex formation, particularly with NMR making clear a neat complexation effect in 
H(3) and H(5). This effect is much stronger in the IB-βCD powder than in the IN-βCD 
one, and justifies the different yields of inclusion into a complex for the two drugs. The 
IB X-ray shows that the process of inclusion provides new patterns to the molecular 
structures. In the IN X-ray the spectra produced before and after the washing process 
with diethyl ether were the same, due to a low inclusion yield. Crystals were present in 
all complexes formed although the ones produced by FD seem to have a higher fraction 
of amorphous material. Different methods produced powders with different moisture 
contents where the FD and SD powders were the ones with less water. 
 
Table 4 
Amount of the drug dissolved at different pHs 
 
Concentration (%)a 
 pH 2 pH 5 pH 7 
Ibuprofen 
IB-βCD PM 43.79 ± 0.69 46.45 ± 1.16 84.56 ± 0.66 
IB-βCD AS 75.71 ± 1.62 79.57 ± 1.03 93.01 ± 1.46 
IB-βCD K30 83.72 ± 0.71   
IB-βCD K70 82.25 ± 1.58   
IB-βCD SD 78.95 ± 1.32 77.99 ± 1.94 71.19 ± 1.33 
IB-βCD FD 78.57 ± 0.83 85.91 ± 0.31 97.02 ± 0.70 
IB 18.70 ± 0.99   
 
    
Indomethacin 
IN-βCD PM 0.48 ± 0.09 3.59 ± 0.67 24.84 ± 0.32 
IN-βCD AS 0.82 ± 0.10 4.32 ± 0.20 24.36 ± 0.29 
IN-βCD K50 0.91 ± 0.16   
IN-βCD K70 0.94 ± 0.18   
IN-βCD SD 1.09 ± 0.18 3.76 ± 0.15 29.59 ± 0.35 
IN-βCD FD 0.95 ± 0.15 4.06 ± 0.79 20.77 ± 1.41 
IN 0.16 ± 0.14   
a) mean±sd (n = 3) 
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